MYRIAD GENETICS, INC. Cost-method Investments, Other than Temporary Impairment
MYRIAD GENETICS, INC. (MYGN) reported Cost-method Investments, Other than Temporary Impairment of $2.40 million for the 12-month period ending 2017-06-30, per its 10-K filed 2019-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostmethodInvestmentsOtherThanTemporaryImpairment · last filed 2019-08-13
- MYRIAD GENETICS, INC. cost-method investments, other than temporary impairment for the quarter ending 2017-06-30 was $0.00.
- MYRIAD GENETICS, INC. cost-method investments, other than temporary impairment for the quarter ending 2017-03-31 was -$100.00K.
- MYRIAD GENETICS, INC. cost-method investments, other than temporary impairment for fiscal 2017 was $2.40M.
| Period end | Cost-method Investments, Other than Temporary Impairment 3 month | Cost-method Investments, Other than Temporary Impairment 6 month | Cost-method Investments, Other than Temporary Impairment 9 month | Cost-method Investments, Other than Temporary Impairment 12 month |
|---|---|---|---|---|
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-13 | -$100.00K derived: sum of 2 quarters · filed 2019-08-13 | $2.40M 10-K · filed 2019-08-13 | |
| 2017-03-31 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $2.40M 10-Q · filed 2018-05-09 | ||
| 2016-12-31 | $2.50M 10-Q · filed 2018-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |